Edition:
United States

Albireo Pharma Inc (ALBO.OQ)

ALBO.OQ on NASDAQ Stock Exchange Capital Market

32.98USD
4:00pm EDT
Change (% chg)

$-0.29 (-0.87%)
Prev Close
$33.27
Open
$33.46
Day's High
$33.88
Day's Low
$32.31
Volume
14,646
Avg. Vol
18,802
52-wk High
$39.67
52-wk Low
$15.31

Chart for

About

Albireo Pharma, Inc., formerly Biodel Inc., is a specialty biopharmaceutical company. It is focused on the development and commercialization of bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI), disorders where improper flow or absorption of bile causes serious medical conditions for which... (more)

Overall

Beta: 1.60
Market Cap(Mil.): $361.07
Shares Outstanding(Mil.): 10.85
Dividend: --
Yield (%): --

Financials

  ALBO.OQ Industry Sector
P/E (TTM): -- 188.22 33.60
EPS (TTM): -3.12 -- --
ROI: -47.75 -0.74 13.19
ROE: -47.77 -2.80 15.00

BRIEF-Albireo Pharma Inc Files For Non-Timely 10-K ‍​

* ALBIREO PHARMA INC FILES FOR NON-TIMELY 10-K WITH THE U.S. SEC ‍​ Source text: (http://bit.ly/2pobWiJ) Further company coverage:

Mar 19 2018

BRIEF-Albireo Reports Fourth Quarter And Year-End 2017 Financial Results

* ALBIREO REPORTS FOURTH QUARTER AND YEAR-END 2017 FINANCIAL RESULTS

Mar 15 2018

BRIEF-Albireo Prices $65.0 Mln Public Offering Of Common Stock

* ALBIREO PRICES $65.0 MILLION PUBLIC OFFERING OF COMMON STOCK

Jan 25 2018

BRIEF-Albireo Pharma Says Elobixibat Approved In Japan For Treatment Of Chronic Constipation

* ALBIREO TO RECEIVE MORE THAN $55 MILLION(1) IN NONDILUTIVE CASH PAYMENTS

Jan 19 2018

BRIEF-Albireo Announces Agreement With Healthcare Royalty Partners

* ALBIREO ANNOUNCES ROYALTY MONETIZATION AGREEMENT WITH HEALTHCARE ROYALTY PARTNERS FOR ELOBIXIBAT IN JAPAN

Jan 03 2018

BRIEF-Albireo posts Q3 loss per share $0.73‍​

* Albireo Pharma Inc - ‍decision on potential approval of elobixibat in Japan expected in first half of 2018​

Nov 14 2017

Competitors

Earnings vs. Estimates